Buy Vivanat solution 1 mg/ml 3 ml syringe 1 pc.

Ibandronic acid

In stock 1317 Items

Available since: 2019-09-19

Dosage form

pills
syringe
solution

Brand & Manufacturer

Package Size

1 mg/ml 3 ml syringe 1 pc.

$190.81

Quantity

All payments are SSL encrypted
Full Refund if you haven't received your order
International shipping to the USA, UK and Europe

Clinical Pharmacology

Bone resorption inhibitor, nitrogen-containing bisphosphonate. It has a selective effect on bone tissue, which is due to the high affinity for hydroxyapatite, which constitutes the mineral matrix of bone. Ibandronic acid suppresses bone resorption and has no direct effect on bone formation.

Ibandronic acid prevents bone destruction caused by the cessation of function of the gonads, retinoids, tumors and extracts of tumors in vivo.

In postmenopausal women, it decreases the increased rate of bone tissue renewal to the level of reproductive age, which leads to a progressive increase in bone mass.

Ibandronic acid prevents the development of new and reduces the growth of existing bone metastases. It has a dose-dependent inhibitory effect on tumor osteolysis.

Indications

Postmenopausal osteoporosis to prevent fractures.

Metastatic bone damage to reduce the risk of hypercalcemia, pathological fractures, reduce pain, reduce the need for radiation therapy for pain syndrome and the threat of fractures.

Hypercalcemia in malignant tumors.

Composition

1 ml:
Sodium ibandronate monohydrate - 1.125 mg, which corresponds to the content of ibandronic acid 1 mg.
Excipients: sodium acetate trihydrate - 0.2 mg, glacial acetic acid - 0.5 mg, sodium chloride - 8.6 mg, acetic acid 1% solution - to pH 3.7-4.0, water d / and - to 1 ml.

Ibandronic acid is marketed under different brands and generic names, and comes in different dosage forms:

Brand name	Manufacturer	Country	Dosage form
Vivanat			solution
Bonviva	Hoffmann la roch	Switzerland	syringe
Bonviva	Hoffmann la roch	Switzerland	pills

No customer reviews for the moment.

Write your review

Dosage and Administration

Apply inside or IV.

The dose and regimen depends on the evidence and the clinical situation.

Adverse reactions

On the part of the digestive system: often - dyspepsia (nausea, abdominal pain), flatulence, diarrhea, constipation, gastritis, gastroenteritis; if ingested, esophagitis, gastroesophageal reflux disease; infrequently by ingestion - esophagitis, including ulceration of the esophagus or stricture, dysphagia, vomiting; rarely - duodenitis.
On the part of the nervous system and psyche: often - headache, dizziness, insomnia.

On the part of the skin and subcutaneous tissues: often - a rash.

Allergic reactions: rarely - angioedema, swelling of the face, urticaria.

On the part of the musculoskeletal system: often - arthralgia, myalgia, pain in the extremities, osteoarthritis, back pain, musculoskeletal pain; infrequently - pain in the bones; rarely, atypical subversion and diaphyseal fractures of the femur (characteristic of the bisphosphonate class); very rarely, osteonecrosis of the jaw.

On the part of the organ of vision: rarely - inflammatory diseases of the eye.

On the part of the body as a whole: often - flu-like syndrome, weakness; infrequently - asthenia.

Others: often - nasopharyngitis, cystitis, urinary tract infections, bronchitis, upper respiratory tract infections, arterial hypertension, hypercholesterolemia; infrequently - reactions at the injection site, phlebitis, thrombophlebitis; rarely, hypersensitivity reactions; With the on / in the introduction of possible short-term decrease in the level of calcium in the serum.

Contraindications

For ingestion and intravenous administration: hypocalcemia, severe renal dysfunction

For oral administration: lesions of the esophagus, leading to a delay in its emptying, such as stricture or achalasia; inability to sit or stand for 60 minutes.

Drug interactions

With simultaneous use with aminoglycosides may develop hypocalcemia (since these active substances reduce the level of calcium in serum for a long time); possible hypomagnesemia.

Pregnancy and Lactation

Contraindicated for use during pregnancy and lactation.

Special instructions

It is used with caution in patients with hypersensitivity to other bisphosphonates.

During treatment, kidney function, plasma levels of calcium, phosphorus and magnesium should be monitored. It is recommended to avoid excessive hydration in patients with circulatory failure.

It should be borne in mind that the use of bisphosphonates can cause bronchospasm in patients with bronchial asthma and in case of hypersensitivity to acetylsalicylic acid.

Do not allow intra-arterial injection.

Products containing calcium and other polyvalent cations (for example, aluminum, magnesium, iron), including milk and solid food may interfere with the absorption of ibandronic acid (they should be consumed no earlier than 30 minutes after oral administration of the drug).